推荐产品
product name
Discovery ® C8 HPLC 色谱柱, 5 μm particle size, L × I.D. 12.5 cm × 4.6 mm
材料
stainless steel column
品質等級
agency
suitable for USP L7
產品線
Discovery®
特點
endcapped
製造商／商標名
Discovery®
包裝
1 ea of
標籤範圍
7.5% Carbon loading
參數
≤70 °C temp. range
400 bar pressure (5801 psi)
技術
HPLC: suitable
LC/MS: suitable
長度 × 內徑
12.5 cm × 4.6 mm
表面積
200 m2/g
表面覆盖率
3.4 μmol/m2
雜質
<10 ppm metals
基質
silica gel, high purity, spherical base material
fully porous particle
基質活性組
C8 (octyl) phase
粒徑
5 μm
孔徑
180 Å
工作pH值範圍
2-8
應用
food and beverages
分離技術
reversed phase
正在寻找类似产品? 访问 产品对比指南
相关类别
M Q Zhang et al.
Die Pharmazie, 46(10), 687-700 (1991-10-01)
The rapid growth in the quinolone research changed the whole face of the previous SAR concepts. So far structural modifications at all positions of the quinolone nucleus except the 4-oxo group have successfully lead to the discovery of potent antimicrobial
G L Bundy et al.
The Journal of biological chemistry, 261(2), 747-751 (1986-01-15)
The gorgonian coral Pseudoplexaura porosa contains a lipoxygenase capable of converting exogenous arachidonic acid into (8R)-8-hydroperoxy-5,9,11,14-eicosatetraenoic acid. The (8R)- (or 8-L-) configuration in this product, opposite to that observed in previously reported 8-lipoxygenase products, was determined unambiguously by comparison of
Hugo M Botelho et al.
Scientific reports, 5, 9038-9038 (2015-03-13)
Plasma membrane proteins are essential molecules in the cell which mediate interactions with the exterior milieu, thus representing key drug targets for present pharma. Not surprisingly, protein traffic disorders include a large range of diseases sharing the common mechanism of
Simeon Grazio et al.
Clinical and experimental rheumatology, 31(5), 665-671 (2013-06-07)
Using proteomic approach in this study, we sought to identify proteins with heparin affinity associated with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and non-inflammatory arthritis (NIA). Plasma samples from adult RA, PsA and NIA patients, 20 of each, were collected.
Scott C Bell et al.
Pharmacology & therapeutics, 145, 19-34 (2014-06-17)
With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic defects of cystic fibrosis (CF) commenced. Pharmacological manipulation provides the opportunity to enhance CF transmembrane conductance regulator (CFTR) protein synthesis and/or function. CFTR
相关内容
Discovery C18 and C8 HPLC Columns products offered
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门